Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$8.870.00 (0.00%)
Exchange :NASDAQ
Volume :0
Today's Open$0.00
Previous Close$8.87
Data as of September 25, 2018 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $8.87 with a 52 week high of $23.97 and a 52 week low of $5.50.

Recent Press Releases

September 24, 2018

Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1 read more

September 19, 2018

Protagonist Therapeutics Reports Granting of Inducement Award read more

September 06, 2018

Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300 read more

Upcoming Events

There are currently no events scheduled.


Download Documentation Investor Presentation
Data provided by Nasdaq. Minimum 15 minutes delayed.